What is NOT expected from the administration of Neostigmine?

Neostigmine is a reversible inhibitor of the enzyme acetylcholinesterase, which leads to an accumulation of acetylcholine at the synaptic cleft. This action enhances cholinergic activity throughout the body, resulting in several physiological effects.

The expected outcomes from the administration of Neostigmine include increased gastric motility, miosis (constriction of the pupils), and increased secretions. These effects are due to its stimulation of the parasympathetic nervous system, which is responsible for 'rest and digest' functions.

However, one particular effect that is NOT associated with Neostigmine is AV conduction delay. While the drug enhances cholinergic activity, leading to various parasympathetic effects, it typically does not result in an AV conduction delay. In fact, Neostigmine is more likely to improve conduction and enhance contractility in certain situations. Thus, recognizing that AV conduction delay is not a typical consequence assists in understanding the broader impact of cholinergic medications like Neostigmine.